Two Maryland-based companies are racing to get a vaccine for respiratory syncytial virus (RSV) to market–and one just picked up a regulatory boost.
MedImmune, AstraZeneca’s ($AZN) biologics research and development arm, announced on Thursday that the FDA is fast-tracking its RSV vaccine, MEDI8897. It joins Novavax ($NVAX), which received FDA fast-track designation for its candidate in November.
The next CONNECTpreneur event is September 28 at the Hyatt Regency Bethesda. More info at connectpreneur.org
There’s a 40% discount code just for eBiz Alert subscribers: Enter CODE: MOCO when you register at http://connectpreneursept2016.eventbrite.com.
This event’s Fireside guest is Seth Goldman, Founder and TeaEO, Honest Tea.
There will be a terrific VC panel including Moderator: Eric Koefoot, Co-Founder and Managing Partner, Public Relay, CEO and Publisher, US News Ventures, Founder and CEO, Five Star Alliance; AJ Jaghori, CEO Solebrity; Founder HelloLoCo; Beth Johnson, Founder and CEO, RP3 Agency; Jeannette Lee, Founder and CEO, Cyper; Founder and CEO, SYTEL.
GlaxoSmithKline’s experimental vaccine to prevent the intensely painful condition known as shingles remained 90 percent effective in people over age 70 even four years after receiving the injection, according to data published on Wednesday.
California Life Sciences Institute (CLSI) today announced the appointment of Heather Shane to build and lead the CLSI CARB-X accelerator, which will provide non-dilutive funding, business support and subject matter expertise to companies with innovative antibiotic product candidates. The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is the world’s largest public-private partnership focused on tackling one of the greatest modern threats to public health — antibiotic resistance. CARB-X will commit $50 million during the first year, and at least $350 million over five years, toward preclinical research and development with the aim of accelerating antibiotic product development over the next 25 years. CLSI is the non-profit partner of the California Life Sciences Association (CLSA), and supports the foundations of innovation – workforce development, STEM education and entrepreneurship – that have made California home to the world’s most prominent life sciences ecosystem.
Crosstown rivals Novartis ($NVS) and Roche ($RHHBY) will be neck and neck for the No. 1 spot in pharma sales till 2022, with Roche ahead by a nose at the finish line, according to a new market analysis. Along the way, a 6.3% annual growth rate industrywide will take global prescription drug sales past the $1 trillion mark.
Accenture has announced the creation of the Accenture HealthTech Innovation Challenge, which aims to bring together startup firms and prominent life sciences and health companies to address challenges including access, affordability, transparency and security.
Alexandria Real Estate (NYSE:ARE) is about as successful a Wall Street story as you’ll find. Started in 1994 as what management fondly recalls as a garage startup, the company now is one of the most successful and unique REITs on the market today. What makes the company so special is that Alexandria was the first REIT to focus exclusively on life science and biotechnology clients, specifically in the most prime real estate markets: Boston, San Francisco, New York City, etc.
Former New York mayor and businessman Michael Bloomberg is giving $300 million to the Johns Hopkins University Bloomberg School of Public Health to help fight drug addiction, obesity and gun violence.
The next CONNECTpreneur event is September 28 at the Hyatt Regency Bethesda. More info at connectpreneur.org
There’s a 40% discount code just for eBiz Alert subscribers: Enter CODE: MOCO when you register at http://connectpreneursept2016.eventbrite.com.
This event’s Fireside guest is Seth Goldman, Founder and TeaEO, Honest Tea.
From Mark Suster:
“I recently read a blog post by Beezer Clarkson, Managing Director of Sapphire Ventures about why entrepreneurs should care about from whom their VC funds raise their capital. I spent a bunch of time thinking about this position — especially since Beezer is an investor in Upfront Ventures. There are a lot of things I think entrepreneurs should care about when raising from a VC:”
